Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Patrick DalyAcute Lymphoblastic Leukemia | July 2, 2024
The US FDA approved blinatumomab for the treatment of CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL.
Read More
Andrew MorenoAcute Lymphoblastic Leukemia | June 6, 2024
Investigators identified pre- and postinfusion factors linked to severe hematotoxicity, as defined by EHA/EBMT criteria.
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Michel Zwaan, MD, PhDAcute Lymphoblastic Leukemia | April 22, 2024
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Melissa BadamoAcute Myeloid Leukemia | April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | April 23, 2024
Efficacy was based on the MRD-negative CR rate at the end of induction.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | April 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | March 6, 2024
The efficacy of inotuzumab ozogamicin was assessed in a multicenter, single-arm, open-label study in 53 pediatric patients.
Melissa BadamoAcute Myeloid Leukemia | May 21, 2024
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
Patrick DalyAcute Lymphoblastic Leukemia | May 21, 2024
Most patients in the lower-dose group achieved complete remission or complete remission with partial hematologic recovery.
Melissa BadamoAcute Myeloid Leukemia | March 1, 2024
The percentage of KMT2A-altered cells decreased from 59.2% to 8.1% after treatment with JNJ-75276617.
Melissa BadamoAcute Lymphoblastic Leukemia | February 23, 2024
53.8% of patients treated with blinatumomab achieved MRD negativity within a median of 3.1 months, as detected with clonoSEQ.
Blood Cancer TalksAcute Myeloid Leukemia | March 4, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Leah SherwoodAcute Lymphoblastic Leukemia | January 31, 2024
The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia.
Leah SherwoodAcute Lymphoblastic Leukemia | January 5, 2024
The approval is based on the clinical results from a single-arm, multicenter, pivotal study in China.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
93% of patients became measurable residual disease (MRD) negative after the first cycle of blinatumomab.
Leah SherwoodAcute Lymphoblastic Leukemia | December 3, 2023
Adding blinatumomab to consolidation chemotherapy represents a new standard of care in newly diagnosed B-lineage ALL.
Melissa BadamoAcute Lymphoblastic Leukemia | November 13, 2023
After a follow-up of 24 months, the two-year relapse free survival was 54% and the two-year overall survival rate was 60%.
Melissa BadamoAcute Lymphoblastic Leukemia | November 13, 2023
The effect of elevated BMI was more pronounced in older adolescent and young adults (AYAs) compared to younger AYAs.
Editorial Board